Gregory P. Forlenza
A5062084555- Diabetes Management and Research
- Pancreatic function and diabetes
- Diabetes and associated disorders
- Diabetes Treatment and Management
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Cardiovascular Function and Risk Factors
- Mobile Health and mHealth Applications
- Pharmaceutical studies and practices
- Diabetes Management and Education
- Spectroscopy Techniques in Biomedical and Chemical Research
- Medication Adherence and Compliance
- Pancreatic and Hepatic Oncology Research
- Metabolism, Diabetes, and Cancer
- Parkinson's Disease Mechanisms and Treatments
- Microfluidic and Capillary Electrophoresis Applications
- Wireless Body Area Networks
- Pancreatitis Pathology and Treatment
- Electrochemical sensors and biosensors
- Retinal Diseases and Treatments
- Metabolism and Genetic Disorders
- Cardiac Imaging and Diagnostics
- Childhood Cancer Survivors' Quality of Life
- Hematopoietic Stem Cell Transplantation
- Oral and Craniofacial Lesions
- Neutropenia and Cancer Infections
University of Colorado Anschutz Medical Campus
2016-2025
University of Colorado Denver
2016-2025
The Medical Center of Aurora
2018-2024
Children's Hospital Colorado
2023-2024
Jaeb Center for Health Research
2020-2022
Massachusetts General Hospital
2022
Children's Hospital of Orange County
2022
The University of Texas Southwestern Medical Center
2022
The University of Texas Health Science Center at San Antonio
2022
Boston University
2016-2022
Closed-loop systems that automate insulin delivery may improve glycemic outcomes in patients with type 1 diabetes.
A closed-loop system of insulin delivery (also called an artificial pancreas) may improve glycemic outcomes in children with type 1 diabetes.
Abstract The significant and growing global prevalence of diabetes continues to challenge people with (PwD), healthcare providers, payers. While maintaining near-normal glucose levels has been shown prevent or delay the progression long-term complications diabetes, a proportion PwD are not attaining their glycemic goals. During past 6 years, we have seen tremendous advances in automated insulin delivery (AID) technologies. Numerous randomized controlled trials real-world studies that use AID...
This study evaluated a new insulin delivery system designed to reduce when trends in continuous glucose monitoring (CGM) concentrations predict future hypoglycemia.Individuals with type 1 diabetes (n = 103, age 6-72 years, mean HbA1c 7.3% [56 mmol/mol]) participated 6-week randomized crossover trial evaluate the efficacy and safety of Tandem Diabetes Care t:slim X2 pump Basal-IQ integrated Dexcom G5 sensor predictive low-glucose suspend algorithm (PLGS) compared sensor-augmented (SAP)...
Advances in diabetes technology have transformed the treatment paradigm for type 1 diabetes, yet burden of disease is significant. We report on a pivotal safety study first tubeless, on-body automated insulin delivery system with customizable glycemic targets.This single-arm, multicenter, prospective enrolled 112 children (age 6-13.9 years) and 129 adults 14-70 years). A 2-week standard therapy phase (usual regimen) was followed by 3 months delivery. Primary outcomes were incidence severe...
Background: A composite metric for the quality of glycemia from continuous glucose monitor (CGM) tracings could be useful assisting with basic clinical interpretation CGM data. Methods: We assembled a data set 14-day 225 insulin-treated adults diabetes. Using balanced incomplete block design, 330 clinicians who were highly experienced analysis and ranked best to worst glycemia. used principal component multiple regressions develop model predict clinician ranking based on seven standard...
To evaluate the safety of in-home use MiniMed™ 670G system with SmartGuard™ technology in children type 1 diabetes (T1D).Participants (N = 105, ages 7-13 years, mean age 10.8 ± 1.8 years) were enrolled at nine centers (eight United States and one Israel) completed a 2-week baseline run-in phase Manual Mode followed by 3-month study Auto enabled. Sensor glucose (SG), glycated hemoglobin (HbA1c), percentage SG values across ranges, variability, during phases compared. Participants underwent...
Background: The current COVID-19 pandemic provides an incentive to expand considerably the use of telemedicine for high-risk patients with diabetes, and especially management type 1 diabetes (T1D). Telemedicine digital medicine also offer critically important approaches improve access, efficacy, efficiency, cost-effectiveness medical care people diabetes. Methods: Two case reports are presented where was used effectively safely after day in person patient education. These aspects new-onset...
Currently available semiautomated insulin-delivery systems require individualized insulin regimens for the initialization of therapy and meal doses based on carbohydrate counting routine operation. In contrast, bionic pancreas is initialized only basis body weight, makes all dose decisions delivers autonomously, uses announcements without counting.
Importance In preclinical studies, thioredoxin-interacting protein overexpression induces pancreatic beta cell apoptosis and is involved in glucotoxicity-induced death. Calcium channel blockers reduce these effects may be beneficial to preservation type 1 diabetes. Objective To determine the effect of verapamil on function children adolescents with newly diagnosed Design, Setting, Participants This double-blind, randomized clinical trial including aged 7 17 years diabetes who weighed 30 kg...
Closed-loop control systems of insulin delivery may improve glycemic outcomes in young children with type 1 diabetes. The efficacy and safety initiating a closed-loop system virtually are unclear.In this 13-week, multicenter trial, we randomly assigned, 2:1 ratio, who were at least 2 years age but younger than 6 had diabetes to receive treatment or standard care that included either an pump multiple daily injections plus continuous glucose monitor. primary outcome was the percentage time...
Importance Near normalization of glucose levels instituted immediately after diagnosis type 1 diabetes has been postulated to preserve pancreatic beta cell function by reducing glucotoxicity. Previous studies have hampered an inability achieve tight glycemic goals. Objective To determine the effectiveness intensive management near on preservation in youth with newly diagnosed diabetes. Design, Setting, and Participants This randomized, double-blind, clinical trial was conducted at 6 centers...
Background: The Omnipod® 5 Automated Insulin Delivery System was associated with favorable glycemic outcomes for people type 1 diabetes (T1D) in two pivotal clinical trials. Real-world evidence is needed to explore effectiveness nonstudy conditions. Methods: A retrospective analysis of the United States Omnipod users (aged ≥2 years) T1D and sufficient data (≥90 days data; ≥75% ≥220 continuous glucose monitor readings/day) available Insulet Corporation's device person-reported datasets as...
Intense exercise is a major challenge to the management of type 1 diabetes (T1D). Closed-loop control (CLC) systems (artificial pancreas) improve glycemic during limited intensity and short duration physical activity (PA). However, CLC has not been tested extended vigorous outdoor common among adolescents.Skiing presents unique metabolic challenges: intense prolonged PA, cold, altitude, stress/fear/excitement. In randomized controlled trial, 32 adolescents with T1D (ages 10-16 years)...
Objective To describe predictors of hybrid closed loop (HCL) discontinuation and perceived barriers to use in youth with type 1 diabetes. Subjects Youth diabetes (eligible age 2-25 y; recruited 8-25 y) who initiated the Minimed 670G HCL system were followed prospectively for 6 mo an observational study. Research Design Methods Demographic, glycemic (time-in-range, HbA1c), psychosocial variables [Hypoglycemia Fear Survey (HFS); Problem Areas Diabetes (PAID)] collected all participants....
To describe glycemic and psychosocial outcomes in youth with type 1 diabetes using a hybrid closed loop (HCL) system.Youth (2-25 years) starting the 670G HCL system for their care were enrolled an observational study.Prospective data collection occurred during routine clinical included variables (sensor time range [70-180 mg/dL], HbA1c), (Hypoglycemia Fear Survey [HFS]; Problem Areas Diabetes [PAID]). Mixed models used to analyze change across time.Ninety-two (mean age 15.7 ± 3.6 years, 50%...
OBJECTIVE The MiniMed 670G System is the first commercial hybrid closed-loop (HCL) system for management of type 1 diabetes. Using data from adolescent and young adult participants, we compared insulin delivery patterns time-in-range metrics in HCL (Auto Mode) open loop (OL). alerts, usage profiles, operational parameters were examined to provide suggestions optimal clinical use system. RESEARCH DESIGN AND METHODS Data 31 participants (14–26 years old) at three sites pivotal trial analyzed....
Background: In this study, we evaluated the analytical performance of second-generation factory-calibrated FreeStyle Libre Flash Glucose Monitoring (FreeStyle 2) System compared to plasma venous blood glucose reference, Yellow Springs Instrument 2300 (YSI). Methods: The study enrolled participants aged four and above with type 1 or 2 diabetes at seven sites in United States. Adult (18+ years) participated three in-clinic sessions pediatric (4-17 up two stratified provide data for days 1, 2,...
IN BRIEF Insulin pump therapy is advancing rapidly. This article summarizes the variety of insulin technologies available to date and discusses important clinical considerations for each type technology.
Skin integrity and diabetes device placement are ongoing concerns for people with who utilize continuous glucose monitors (CGMs) subcutaneous insulin infusion pumps. This is especially significant individuals skin sensitivities, pediatric patients, those use devices chronically. Dermatological complications often cited as a barrier to reason discontinuation. Furthermore, it frequent topic of discussion in follow-up visits, although little evidence-based literature exists guide providers...
A fully closed-loop insulin-only system was developed to provide glucose control in patients with type 1 diabetes without requiring announcement of meals or activity. Our goal assess initial safety and efficacy this system.The multiple model probabilistic controller (MMPPC) anticipates when the patient is awake. The used subject's basal rates total daily insulin dose for initialization. tested at two sites on 10 a 30-h inpatient study, followed by 15 subjects three 54-h supervised hotel...
Hybrid closed-loop (HCL) artificial pancreas (AP) systems are now moving from research settings to widespread clinical use. In this study, the inControl algorithm developed by TypeZero Technologies was embedded a commercial Tandem t:slim X2 insulin pump, called Control-IQ, paired with Dexcom G6 continuous glucose monitor and tested for superiority against sensor augmented pump (SAP) therapy. Both groups were physician-monitored throughout trial.In randomized controlled trial, 24 school-aged...